Medifast - MED Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MED shares.
View MED analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price objectives for Medifast's shares. Their MED share price forecasts range from $150.00 to $278.00. On average, they expect the company's share price to reach $214.00 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $209.43 on January 1st, 2022. Since then, MED stock has decreased by 31.8% and is now trading at $142.87.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) announced its quarterly earnings results on Thursday, November, 4th. The specialty retailer reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.64. The specialty retailer earned $413.40 million during the quarter, compared to analysts' expectations of $402.80 million. Medifast had a net margin of 9.44% and a trailing twelve-month return on equity of 87.11%. The company's quarterly revenue was up 52.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.91 earnings per share.

Medifast declared a quarterly dividend on Saturday, June 18th. Stockholders of record on Tuesday, June 28th will be given a dividend of $1.64 per share on Monday, August 8th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 4.59%. The ex-dividend date is Monday, June 27th.
Read our dividend analysis for MED.

Medifast (NYSE:MED) pays an annual dividend of $6.56 per share and currently has a dividend yield of 4.74%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 48.66%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 49.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MED.

Medifast issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of $12.70-$14.10 for the period, compared to the consensus estimate of $15.38. The company issued revenue guidance of $1.58 billion-$1.66 billion, compared to the consensus revenue estimate of $1.81 billion.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.90%), State Street Corp (3.43%), Rice Hall James & Associates LLC (2.74%), Principal Financial Group Inc. (2.20%), Pictet Asset Management SA (1.65%) and Victory Capital Management Inc. (1.12%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $142.87.

Medifast (NYSE:MED) has a market capitalization of $1.57 billion and generates $1.53 billion in revenue each year. The specialty retailer earns $164.03 million in net income (profit) each year or $13.48 on an earnings per share basis.

The company employs 984 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.